Developer docs
API playgroundTry for free, no card

Search company profiles

Bionorica SE

Full company profile

uuid000c1fl

Namestring
Bionorica SE
Legal namestring
Bionorica SE
Websiteurl
bionorica.de
Company typeenum
Private
Founded yearint
1933
Descriptiontext

Bionorica SE is a German, family-owned pharmaceutical manufacturer founded in 1933 and headquartered in Neumarkt in der Oberpfalz, Bavaria. The company develops, produces, and distributes scientifically validated herbal medicines (rational phytopharmaceuticals) under its proprietary "Phytoneering" methodology — a vertically integrated approach spanning proprietary seed selection, GACP-compliant cultivation (its own land on Mallorca plus contract farmers in Austria, France, and Hungary), controlled extraction including proprietary vacuum drying to preserve essential oils and flavonoids, and clinical validation through more than 500 partner universities, clinics, and research institutes worldwide. The portfolio is organized around six therapeutic areas: respiratory (Sinupret, Bronchipret, Imupret N, Tonsipret), urology (Canephron), gynecology (Agnucaston, Mastodynon, Klimadynon), dermatology (Bionorica Derma Line), liver (Silimarit), and digestion (Digestopret). The company also operates Phytoneering Extract Solutions GmbH, a B2B subsidiary selling plant extracts, distillates, tinctures, and fresh plant juices to pharmaceutical, cosmetics, veterinary, and food supplement customers.

Bionorica generates revenue primarily through one-time sales of branded OTC phytopharmaceutical products distributed through pharmacy channels in more than 45 countries. Distribution uses a hybrid model: own scientific field sales forces and dedicated sales branches in Germany, Austria, Poland, Russia, Spain (Madrid opened July 2024), and other key markets, supplemented by local distribution partners and pharmacy cooperative (Apothekenkooperationen) relationships in additional geographies. The Phytothek pharmacy partnership concept and direct physician education drive recommendation-led demand. Pricing is not publicly disclosed but reflects branded OTC positioning. In 2025 the Bionorica Group generated €559 million in revenue with a reported 88.5% equity ratio, employed more than 2,370 people globally (with the majority in Germany), and held market-leading positions in phytopharmaceuticals in Germany, Russia, and large parts of Eurasia. The company has been continuously owned and led by the Popp family across three generations, with Prof. Dr. Michael A. Popp serving as CEO since 1989.

Short descriptiontext

Bionorica SE is a German, family-owned pharmaceutical manufacturer founded in 1933 that develops and sells scientifically validated herbal medicines (Sinupret, Bronchipret, Canephron, and other brands) through pharmacies in more than 45 countries, generating €559 million in 2025 revenue with leading market positions in phytopharmaceuticals across Germany, Russia, and Eurasia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersNeumarkt In Der Oberpfalz, Germany
HQ citystring
Neumarkt In Der Oberpfalz
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
herbal medicines, phytopharmaceutical products, plant-based therapeutics, OTC pharmaceuticals, botanical drug manufacturing
Industry1 code
PRIMARYAFAJAKAD
Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Phytopharmaceuticals (Herbal Medicines)
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Phytopharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from sales of herbal medicinal products across therapeutic areas including respiratory, women's health, urology, liver, and digestive health. Products are sold in over 45 countries with market leadership positions in Germany, Russia, and large parts of Eurasia.

bionorica.de
2Phytoneering Extract Solutions GmbH
TypeOne Time License
Description

Subsidiary company selling plant extracts, distillates, tinctures, and fresh plant juices to external customers for use in pharmaceutical products, cosmetics, veterinary medicine, and food supplements. Also focuses on active ingredients derived from fiber hemp that do not fall under narcotics legislation.

bionorica.de
3Bionorica extracts S.L.
TypeOne Time License
Description

Spanish subsidiary on Mallorca handles cultivation of medicinal plants, direct extract production, and quality control. Produces thyme extracts for Bronchipret and serves external customers of Phytoneering Extract Solutions GmbH.

bionorica.de
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Phytoneering Extract Solutions GmbH
Description

Subsidiary dealing with sales of plant extracts, distillates, tinctures and fresh plant juices for pharmaceuticals, cosmetics, veterinary medicine and food supplements

bionorica.de
+6 more records
Core offering1 text field

Bionorica SE develops, manufactures, and markets scientifically researched herbal medicinal products (phytopharmaceuticals) under its proprietary "Phytoneering" methodology. The product portfolio spans respiratory health, urology, gynecology, medical skincare, liver support, and digestive health, and is sold primarily through pharmacy channels in more than 45 countries. The company also produces and sells standardized plant extracts to external pharmaceutical, cosmetics, veterinary, and food supplement manufacturers via its subsidiary Phytoneering Extract Solutions GmbH.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Sinupret is the best-selling cold remedy in Germany by revenue (IQVIA OTC Report)
+3 more records
Product overview1 text field

Bionorica SE is a leading global manufacturer of scientifically researched herbal medicines (phytopharmaceuticals) headquartered in Neumarkt, Germany, with over 2,300 employees. The company's product portfolio follows a multi-brand, multi-indication strategy organized around six therapeutic areas: respiratory tract (Atemwege), urinary tract (Harnwege), gynecology (Gynäkologie), medical skincare (Medizinische Hautpflege), digestion (Verdauung), and liver (Leber). The core product lines include Sinupret® (sinusitis treatment with 5-plant combination available in eXtract, forte, tablet, juice, and drop forms), Bronchipret® (cough/bronchitis remedy with thyme/ivy in liquid, drop, tablet, and lozenge forms), Imupret® N (cold prevention with 7-plant combination in drops and tablets), Tonsipret® (sore throat treatment in tablets and drops), Canephron®/Uno (urinary tract support with rosemary/lovage/centaury in multiple formulations), Agnucaston® (PMS/cycle disorders with vitex), Mastodynon® (breast tension with vitex in tablets and liquid), Klimadynon® (menopause symptoms with black cohosh), Bionorica® Derma Line (medical skincare for dry skin/eczema), Digestopret® (digestive disorders/irritable bowel), and Silimarit® (liver support with milk thistle). The company operates under its proprietary 'Phytoneering' methodology, combining traditional plant medicine with modern pharmaceutical research.

Product and service12 records
1Sinupret
CategoryRespiratory Health - Sinusitis Treatment
Description

Herbal medicinal product for treating acute and chronic sinusitis; combines five medicinal plants (primrose, gentian, sorrel, elder, and verbena) to relieve mucus, open nasal passages, and reduce pressure headaches. Available in tablets, juice, drops, forte, and eXtract dosage forms. Germany's best-selling cold remedy by revenue.

2Bronchipret
CategoryRespiratory Health - Cough and Bronchitis Treatment
Description

Herbal cough and bronchial remedy combining thyme and ivy extracts; provides 3-fold effect calming cough, loosening mucus, and combating inflammation. Marketed as Germany's leading herbal cough remedy. Available as syrup, drops, film-coated tablets, and thyme lozenges.

3Imupret N
CategoryRespiratory Health - Immune Support and Cold Prevention
Description

Herbal cold prevention and treatment product featuring a 7-plant combination (chamomile, marshmallow, horsetail, yarrow, walnut, dandelion, oak); strengthens immune defense and combats cold progression. Available in dragees and drops.

4Tonsipret
CategoryRespiratory Health - Sore Throat Treatment
Description

Herbal sore throat treatment combining medicinal paprika (capsaicin), phytolacca, and lignum vitae; capsaicin inhibits throat pain while other ingredients combat inflammation. Available in tablets and drops.

5Canephron
CategoryUrology - Urinary Tract Infection Treatment
Description

Traditional herbal medicinal product for urinary tract infections combining rosemary leaves, lovage root, and centaury; provides pain-relieving, antispasmodic, bacteria-flushing, and anti-inflammatory effects. Available as Uno (once-daily), N Dragees, and N Tropfen. Proven non-inferior to antibiotics in acute uncomplicated cystitis in a 2018 international clinical study.

6Agnucaston 20 mg
CategoryGynecology - Menstrual and PMS Treatment
Description

Herbal product containing vitex agnus-castus (monk's pepper) for treating menstrual disorders, PMS symptoms, and cycle irregularities in women.

7Mastodynon
CategoryGynecology - Premenstrual Breast Tension
Description

Herbal preparation for treating breast tension and swelling associated with premenstrual syndrome, containing vitex agnus-castus and other botanical ingredients. Available as tablets and liquid mixture.

8Klimadynon
CategoryGynecology - Menopausal Symptom Treatment
Description

Herbal product containing black cohosh (Cimicifuga racemosa) for treating menopausal symptoms including hot flashes, depressive moods, and sleep disturbances. Available as Klimadynon Uno once-daily formulation.

9Bionorica Derma Line
CategoryMedical Skin Care - Atopic Dermatitis and Dry Skin
Description

Medical skincare line for people with dry skin and atopic dermatitis (neurodermatitis), developed by the herbal medicine manufacturer.

10Digestopret
CategoryDigestive Health - IBS and Digestive Disorders
Description

Herbal preparation for treating persistent and recurring digestive disorders, including irritable bowel syndrome symptoms.

11Silimarit
CategoryLiver Health - Liver Disorder Support
Description

Herbal liver product containing standardized silymarin extract from milk thistle (Silybum marianum) for liver disorder support.

12Phytoneering Extract Solutions (B2B Plant Extracts)
CategoryB2B Plant Extract Supply
Description

Subsidiary offering wholesale plant extracts, distillates, tinctures, and fresh plant juices to external customers in the pharmaceutical, cosmetics, veterinary medicine, and food supplement industries. Also offers active ingredients derived from fiber hemp that do not fall under narcotics legislation.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Michael Popp Institut für pflanzliche Wirkstoffforschung (University of Innsbruck)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Opened January 2020 as one of the largest research facilities for plant substance research in Austria. Two endowed professorships funded by the State of Tyrol and Michael A. Popp nature science foundation with approximately 5 million Euro total investment. Goal is to research the healing power of plants and develop new therapy approaches for common diseases.

bionorica.de
2Over 500 Universities and Research Institutions (Global Research Network)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-01-01
Description

Bionorica cooperates with over 500 leading institutes, clinics and universities worldwide for research and development of phytopharmaceuticals. Particularly intensive cooperation with partners in Innsbruck, in the Phytovalley - a globally unique center for natural substance research.

bionorica.de
3Austrian Drug Screening Institute (ADSI)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-11-01
Description

Research company of Leopold-Franzens University Innsbruck dedicated to drug screening - systematic search for new active ingredients and development of new methods. Bionorica is exclusive partner in phyto research. Joint goal: comprehensive pharmacological and analytical characterization of medicinal plant extracts.

bionorica.de
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Two-year partnership announced March 2025 for evidence-based strategies in consumer marketing. Bionorica will work with the institute to apply cutting-edge marketing science to their consumer communications.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Long-term research cooperation agreed with sale of Bionorica's cannabis division to Canopy Growth Corporation effective May 1, 2019. Bionorica sold its cannabis business while maintaining research collaboration in this area.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Bayer Consumer Health
TypeBroad incumbent
Description

Large consumer health division of Bayer AG offering herbal and OTC brands (e.g., Aspirin, Iberogast) via global pharmacy retail; broader portfolio but overlapping channels and indications.

TypeBroad incumbent
Description

Global consumer healthcare spin-off from GSK with leading OTC and natural health brands; competes with Bionorica in respiratory, women's health and pharmacy distribution at much larger scale.

3A. Vogel / Bioforce
TypeDirect peer
Description

Swiss herbal medicine company selling standardized plant-based OTC products through pharmacy channels across Europe; comparable to Bionorica in therapeutic areas (respiratory, women's health) and natural-claim branding.

TypeDirect peer
Description

German manufacturer of herbal medicinal products, teas and natural cosmetics, distributed through pharmacies and health-food retail; overlaps with Bionorica in plant-based OTC and the DACH pharmacy channel.

TypeRegional player
Description

Polish herbal medicinal products manufacturer and Bionorica's direct regional competitor in Central Europe; similar phytoneering-style product portfolio but primarily focused on the Polish and CEE markets.

TypeDirect peer
Description

German family-owned manufacturer of clinically researched herbal medicines (e.g., Tebonin/Kinkgo, Crataegutt, Valverde), directly comparable to Bionorica in business model, channel mix and phytopharmaceutical positioning.

TypeDirect peer
Description

French global leader in homeopathic and herbal medicinal products sold through pharmacies worldwide; similar pharmacy-led GTM, multi-country distribution and emphasis on natural OTC alternatives.

TypeDirect peer
Description

German family-owned OTC pharmaceutical company with strong positions in respiratory (Prospan) and dermatology, comparable to Bionorica in size, channel focus and herbal-versus-synthetic OTC positioning.

9Boehringer Ingelheim (Consumer Health)
TypeBroad incumbent
Description

Family-owned German pharmaceutical group with a consumer healthcare portfolio that includes herbal/plant-based OTC products (e.g., Mucosolvan, Bisolvon), comparable in DACH footprint and pharmacy-led GTM.

TypeBroad incumbent
Description

Sanofi's consumer healthcare business markets herbal and OTC products (e.g., Mucosolvan, Dulcolax) via global pharmacy channels, comparable in channel and OTC positioning, though not specializing in phytos.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bionorica SE

Phytopharmaceuticals (Herbal Medicines)bionorica.de

Bionorica SE is a German, family-owned pharmaceutical manufacturer founded in 1933 that develops and sells scientifically validated herbal medicines (Sinupret, Bronchipret, Canephron, and other brands) through pharmacies in more than 45 countries, generating €559 million in 2025 revenue with leading market positions in phytopharmaceuticals across Germany, Russia, and Eurasia.

What Bionorica SE does

Bionorica SE is a German, family-owned pharmaceutical manufacturer founded in 1933 and headquartered in Neumarkt in der Oberpfalz, Bavaria. The company develops, produces, and distributes scientifically validated herbal medicines (rational phytopharmaceuticals) under its proprietary "Phytoneering" methodology — a vertically integrated approach spanning proprietary seed selection, GACP-compliant cultivation (its own land on Mallorca plus contract farmers in Austria, France, and Hungary), controlled extraction including proprietary vacuum drying to preserve essential oils and flavonoids, and clinical validation through more than 500 partner universities, clinics, and research institutes worldwide. The portfolio is organized around six therapeutic areas: respiratory (Sinupret, Bronchipret, Imupret N, Tonsipret), urology (Canephron), gynecology (Agnucaston, Mastodynon, Klimadynon), dermatology (Bionorica Derma Line), liver (Silimarit), and digestion (Digestopret). The company also operates Phytoneering Extract Solutions GmbH, a B2B subsidiary selling plant extracts, distillates, tinctures, and fresh plant juices to pharmaceutical, cosmetics, veterinary, and food supplement customers.

Bionorica generates revenue primarily through one-time sales of branded OTC phytopharmaceutical products distributed through pharmacy channels in more than 45 countries. Distribution uses a hybrid model: own scientific field sales forces and dedicated sales branches in Germany, Austria, Poland, Russia, Spain (Madrid opened July 2024), and other key markets, supplemented by local distribution partners and pharmacy cooperative (Apothekenkooperationen) relationships in additional geographies. The Phytothek pharmacy partnership concept and direct physician education drive recommendation-led demand. Pricing is not publicly disclosed but reflects branded OTC positioning. In 2025 the Bionorica Group generated €559 million in revenue with a reported 88.5% equity ratio, employed more than 2,370 people globally (with the majority in Germany), and held market-leading positions in phytopharmaceuticals in Germany, Russia, and large parts of Eurasia. The company has been continuously owned and led by the Popp family across three generations, with Prof. Dr. Michael A. Popp serving as CEO since 1989.

Bionorica SE firmographics

Firmographics
Name
Bionorica SE
Legal name
Bionorica SE
Website
https://bionorica.de
Company type
Private
Founded year
1933
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Bionorica SE is a German, family-owned pharmaceutical manufacturer founded in 1933 that develops and sells scientifically validated herbal medicines (Sinupret, Bronchipret, Canephron, and other brands) through pharmacies in more than 45 countries, generating €559 million in 2025 revenue with leading market positions in phytopharmaceuticals across Germany, Russia, and Eurasia.
Ownership category
akta.pro rank

Bionorica SE industry classification

Industry
Product category
Phytopharmaceuticals (Herbal Medicines)
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYAFAJAKAD
Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)

Keywords

  • Herbal medicines
  • Phytopharmaceutical products
  • Plant-based therapeutics
  • OTC pharmaceuticals
  • Botanical drug manufacturing

Where Bionorica SE is headquartered

Location

Headquarters

HQ city
Neumarkt In Der Oberpfalz
HQ country
Germany
HQ region
Europe

Offices6 records

Markets served

Bionorica SE business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Phytopharmaceutical Product Sales: Revenue generated from sales of herbal medicinal products across therapeutic areas including respiratory, women's health, urology, liver, and digestive health. Products are sold in over 45 countries with market leadership positions in Germany, Russia, and large parts of Eurasia.
  2. Phytoneering Extract Solutions GmbH: Subsidiary company selling plant extracts, distillates, tinctures, and fresh plant juices to external customers for use in pharmaceutical products, cosmetics, veterinary medicine, and food supplements. Also focuses on active ingredients derived from fiber hemp that do not fall under narcotics legislation.
  3. Bionorica extracts S.L. Spanish subsidiary on Mallorca handles cultivation of medicinal plants, direct extract production, and quality control. Produces thyme extracts for Bronchipret and serves external customers of Phytoneering Extract Solutions GmbH.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Bionorica SE product offering

Product offering

Core offering

Bionorica SE develops, manufactures, and markets scientifically researched herbal medicinal products (phytopharmaceuticals) under its proprietary "Phytoneering" methodology. The product portfolio spans respiratory health, urology, gynecology, medical skincare, liver support, and digestive health, and is sold primarily through pharmacy channels in more than 45 countries. The company also produces and sells standardized plant extracts to external pharmaceutical, cosmetics, veterinary, and food supplement manufacturers via its subsidiary Phytoneering Extract Solutions GmbH.

Product overview

Bionorica SE is a leading global manufacturer of scientifically researched herbal medicines (phytopharmaceuticals) headquartered in Neumarkt, Germany, with over 2,300 employees. The company's product portfolio follows a multi-brand, multi-indication strategy organized around six therapeutic areas: respiratory tract (Atemwege), urinary tract (Harnwege), gynecology (Gynäkologie), medical skincare (Medizinische Hautpflege), digestion (Verdauung), and liver (Leber). The core product lines include Sinupret® (sinusitis treatment with 5-plant combination available in eXtract, forte, tablet, juice, and drop forms), Bronchipret® (cough/bronchitis remedy with thyme/ivy in liquid, drop, tablet, and lozenge forms), Imupret® N (cold prevention with 7-plant combination in drops and tablets), Tonsipret® (sore throat treatment in tablets and drops), Canephron®/Uno (urinary tract support with rosemary/lovage/centaury in multiple formulations), Agnucaston® (PMS/cycle disorders with vitex), Mastodynon® (breast tension with vitex in tablets and liquid), Klimadynon® (menopause symptoms with black cohosh), Bionorica® Derma Line (medical skincare for dry skin/eczema), Digestopret® (digestive disorders/irritable bowel), and Silimarit® (liver support with milk thistle). The company operates under its proprietary 'Phytoneering' methodology, combining traditional plant medicine with modern pharmaceutical research.

Differentiator

Problem solved

Functional benefit

Brands

  • Phytoneering Extract Solutions GmbH: Subsidiary dealing with sales of plant extracts, distillates, tinctures and fresh plant juices for pharmaceuticals, cosmetics, veterinary medicine and food supplements
  • Bionorica research GmbH
  • Bionorica extracts S.L.
  • Phytothek
  • Natureheart Foundation for Kids
  • Michael Popp Institut
  • Phytovalley

Products and services

  • Sinupret Herbal medicinal product for treating acute and chronic sinusitis; combines five medicinal plants (primrose, gentian, sorrel, elder, and verbena) to relieve mucus, open nasal passages, and reduce pressure headaches. Available in tablets, juice, drops, forte, and eXtract dosage forms. Germany's best-selling cold remedy by revenue.
  • Bronchipret Herbal cough and bronchial remedy combining thyme and ivy extracts; provides 3-fold effect calming cough, loosening mucus, and combating inflammation. Marketed as Germany's leading herbal cough remedy. Available as syrup, drops, film-coated tablets, and thyme lozenges.
  • Imupret N Herbal cold prevention and treatment product featuring a 7-plant combination (chamomile, marshmallow, horsetail, yarrow, walnut, dandelion, oak); strengthens immune defense and combats cold progression. Available in dragees and drops.
  • Tonsipret Herbal sore throat treatment combining medicinal paprika (capsaicin), phytolacca, and lignum vitae; capsaicin inhibits throat pain while other ingredients combat inflammation. Available in tablets and drops.
  • Canephron Traditional herbal medicinal product for urinary tract infections combining rosemary leaves, lovage root, and centaury; provides pain-relieving, antispasmodic, bacteria-flushing, and anti-inflammatory effects. Available as Uno (once-daily), N Dragees, and N Tropfen. Proven non-inferior to antibiotics in acute uncomplicated cystitis in a 2018 international clinical study.
  • Agnucaston 20 mg Herbal product containing vitex agnus-castus (monk's pepper) for treating menstrual disorders, PMS symptoms, and cycle irregularities in women.
  • Mastodynon Herbal preparation for treating breast tension and swelling associated with premenstrual syndrome, containing vitex agnus-castus and other botanical ingredients. Available as tablets and liquid mixture.
  • Klimadynon Herbal product containing black cohosh (Cimicifuga racemosa) for treating menopausal symptoms including hot flashes, depressive moods, and sleep disturbances. Available as Klimadynon Uno once-daily formulation.
  • Bionorica Derma Line Medical skincare line for people with dry skin and atopic dermatitis (neurodermatitis), developed by the herbal medicine manufacturer.
  • Digestopret Herbal preparation for treating persistent and recurring digestive disorders, including irritable bowel syndrome symptoms.
  • Silimarit Herbal liver product containing standardized silymarin extract from milk thistle (Silybum marianum) for liver disorder support.
  • Phytoneering Extract Solutions (B2B Plant Extracts) Subsidiary offering wholesale plant extracts, distillates, tinctures, and fresh plant juices to external customers in the pharmaceutical, cosmetics, veterinary medicine, and food supplement industries. Also offers active ingredients derived from fiber hemp that do not fall under narcotics legislation.

Quantifiable outcome

  • Sinupret is the best-selling cold remedy in Germany by revenue (IQVIA OTC Report)
  • +3 more outcomes

Companies that use Bionorica SE

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Bionorica SE technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Bionorica SE partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Michael Popp Institut für pflanzliche Wirkstoffforschung (University of Innsbruck)coreStrategic or Co-development Partner · 1 January 2020Opened January 2020 as one of the largest research facilities for plant substance research in Austria. Two endowed professorships funded by the State of Tyrol and Michael A. Popp nature science foundation with approximately 5 million Euro total investment. Goal is to research the healing power of plants and develop new therapy approaches for common diseases.
  • Over 500 Universities and Research Institutions (Global Research Network)coreStrategic or Co-development Partner · 1 January 2013Bionorica cooperates with over 500 leading institutes, clinics and universities worldwide for research and development of phytopharmaceuticals. Particularly intensive cooperation with partners in Innsbruck, in the Phytovalley - a globally unique center for natural substance research.
  • Austrian Drug Screening Institute (ADSI)coreStrategic or Co-development Partner · 1 November 2012Research company of Leopold-Franzens University Innsbruck dedicated to drug screening - systematic search for new active ingredients and development of new methods. Bionorica is exclusive partner in phyto research. Joint goal: comprehensive pharmacological and analytical characterization of medicinal plant extracts.
  • Ehrenberg-Bass Institute for Marketing Science (Australia)minorStrategic or Co-development PartnerTwo-year partnership announced March 2025 for evidence-based strategies in consumer marketing. Bionorica will work with the institute to apply cutting-edge marketing science to their consumer communications.
  • Canopy Growth CorporationminorStrategic or Co-development PartnerLong-term research cooperation agreed with sale of Bionorica's cannabis division to Canopy Growth Corporation effective May 1, 2019. Bionorica sold its cannabis business while maintaining research collaboration in this area.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Bionorica SE competitors and assessment

Company assessment

Broad incumbents

  • Bayer Consumer Health: Large consumer health division of Bayer AG offering herbal and OTC brands (e.g., Aspirin, Iberogast) via global pharmacy retail; broader portfolio but overlapping channels and indications.
  • Haleon: Global consumer healthcare spin-off from GSK with leading OTC and natural health brands; competes with Bionorica in respiratory, women's health and pharmacy distribution at much larger scale.
  • Boehringer Ingelheim (Consumer Health): Family-owned German pharmaceutical group with a consumer healthcare portfolio that includes herbal/plant-based OTC products (e.g., Mucosolvan, Bisolvon), comparable in DACH footprint and pharmacy-led GTM.
  • Sanofi Consumer Healthcare: Sanofi's consumer healthcare business markets herbal and OTC products (e.g., Mucosolvan, Dulcolax) via global pharmacy channels, comparable in channel and OTC positioning, though not specializing in phytos.

Direct peers

  • A. Vogel / Bioforce: Swiss herbal medicine company selling standardized plant-based OTC products through pharmacy channels across Europe; comparable to Bionorica in therapeutic areas (respiratory, women's health) and natural-claim branding.
  • Salus-Haus: German manufacturer of herbal medicinal products, teas and natural cosmetics, distributed through pharmacies and health-food retail; overlaps with Bionorica in plant-based OTC and the DACH pharmacy channel.
  • Dr. Willmar Schwabe Pharmaceuticals: German family-owned manufacturer of clinically researched herbal medicines (e.g., Tebonin/Kinkgo, Crataegutt, Valverde), directly comparable to Bionorica in business model, channel mix and phytopharmaceutical positioning.
  • Boiron: French global leader in homeopathic and herbal medicinal products sold through pharmacies worldwide; similar pharmacy-led GTM, multi-country distribution and emphasis on natural OTC alternatives.
  • Engelhard Arzneimittel: German family-owned OTC pharmaceutical company with strong positions in respiratory (Prospan) and dermatology, comparable to Bionorica in size, channel focus and herbal-versus-synthetic OTC positioning.

Regional players

  • Phytopharm Klęka: Polish herbal medicinal products manufacturer and Bionorica's direct regional competitor in Central Europe; similar phytoneering-style product portfolio but primarily focused on the Polish and CEE markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Bionorica SE social profiles

Digital presence

Bionorica SE compliance and trust

Trust signal

Compliance2 records

Bionorica SE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bionorica SE leadership team

Management profile

Number of profiles

Profiles4 records

Bionorica SE subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Bionorica SE funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bionorica SE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionorica SE

What does Bionorica SE do?

Bionorica SE develops, manufactures, and markets scientifically researched herbal medicinal products (phytopharmaceuticals) under its proprietary "Phytoneering" methodology. The product portfolio spans respiratory health, urology, gynecology, medical skincare, liver support, and digestive health, and is sold primarily through pharmacy channels in more than 45 countries. The company also produces and sells standardized plant extracts to external pharmaceutical, cosmetics, veterinary, and food supplement manufacturers via its subsidiary Phytoneering Extract Solutions GmbH.

Is Bionorica SE a public or private company?

Bionorica SE is a private company. It is classified as family owned and is currently operating.

When was Bionorica SE founded?

Bionorica SE was founded in 1933. It employs 1,001 to 5,000 people.

Where is Bionorica SE based?

Bionorica SE is headquartered in Neumarkt In Der Oberpfalz, Germany, in the Europe region.

How does Bionorica SE make money?

Three revenue lines are on record. Phytopharmaceutical Product Sales are the primary driver. The others are phytoneering Extract Solutions GmbH and bionorica extracts S.L.

Who are Bionorica SE's main competitors?

Broad incumbents on record are Bayer Consumer Health, Haleon, Boehringer Ingelheim (Consumer Health) and Sanofi Consumer Healthcare. Direct peers are A. Vogel / Bioforce, Salus-Haus, Dr. Willmar Schwabe Pharmaceuticals, Boiron and Engelhard Arzneimittel. Phytopharm Klęka is listed as a regional player.

Does Bionorica SE have an API?

No public API is recorded for Bionorica SE.

What industry is Bionorica SE in?

Bionorica SE's product category is Phytopharmaceuticals (Herbal Medicines). Its primary akta.pro industry code is AFAJAKAD, Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SciTechDailyA Cannabis-Based Drug Dramatically Reduced PTSD NightmaresResearchers at Charité – Universitätsmedizin Berlin conducted a double-blind trial demonstrating that Dronabinol, a prescription THC medication, significantly reduced PTSD-related nightmares in over 170 participants. The study reported that more than one-third of patients experienced complete disappearance of nightmares, with the treatment group showing greater symptom reduction compared to placebo. The research was supported by an unrestricted grant and provided with study medication by Bionorica SE.PR NewswireBionorica sélectionne les services et les solutions de Movilitas pour assurer la conformité à la loi russe sur la sérialisationBionorica, a major German manufacturer of herbal medicines, selected Movilitas technical services to integrate its SAP Advanced Track and Trace for Pharmaceuticals solution with Russia's MDLP system for compliance with Russian serialization law. The Movilitas.Cloud solution enabled direct connection to the Russian system for crypto code exchange without requiring local installation, production line modifications, or changes to existing SAP configuration. The integration was completed ahead of the January 1, 2020 regulatory deadline.PR NewswireBionorica elige los servicios y las soluciones de Movilitas para cumplir con la ley de serialización rusaBionorica selected Movilitas to implement a compliance solution for Russia's pharmaceutical serialization law, integrating SAP Advanced Track and Trace for Pharmaceuticals with the Russian MDLP system. The partnership utilizes Movilitas.Cloud to facilitate legal transaction monitoring and notification without requiring local installations or changes to Bionorica's existing production environment. This arrangement ensures Bionorica meets the regulatory deadline of January 1, 2020.PR NewswireBionorica setzt auf Services und Lösungen von Movilitas, um Compliance mit neuen russischen Serialisierungsvorschriften zu gewährleistenMovilitas has partnered with pharmaceutical manufacturer Bionorica to integrate its Movilitas.Cloud SaaS solution with Bionorica's SAP Advanced Track and Trace for Pharmaceuticals system. This integration enables compliance with Russia's new MDLP serialisation regulations by facilitating the exchange of crypto-codes between Bionorica and the Russian tracking system. The partnership allows Bionorica to meet the regulatory deadline of January 1, 2020, without requiring local installations or modifications to its production line.PR NewswireBionorica selects Movilitas Services and Solutions for Compliance with the Russian Serialization LawBionorica, a leading global manufacturer of herbal medicines based in Germany, has selected Movilitas technical services to integrate its SAP Advanced Track and Trace for Pharmaceuticals solution directly with Russia's MDLP System for compliance with the Russian serialization law. The integration, powered by Movilitas.Cloud, enables Bionorica to exchange crypto codes and meet legal reporting requirements without local installations or modifications to existing systems. The compliance solution was implemented ahead of the January 1, 2020, deadline set by Russian regulations.PR NewswireCanopy Growth Introduces Spectrum TherapeuticsCanopy Growth Corporation introduced Spectrum Therapeutics as a unified global brand that will encompass all of the company's medical and research operations, including Spectrum Cannabis, Canopy Health Innovations (CHI), and the recently acquired C3 Cannabinoid Compound Company from Bionorica SE. The new brand creates a comprehensive global healthcare enterprise focused on medical cannabis, operating across 12 countries with 11 therapeutic trials planned or ongoing and over 1,800 patients enrolled in studies. The integration positions Canopy Growth as a healthcare company driving broader acceptance of cannabinoid-based medicines as mainstream treatment options.BenzingaCanopy Growth Acquires Germany-Based C3 Cannabinoid Compound Company For $254M - Canopy Growth (NASDAQ:CGCanopy Growth acquired Germany-based C3 Cannabinoid for $254 million in all cash. The deal gives Canopy access to C3's dronabinol patents and clinical research, expanding its European presence. C3 served 19,500 patients in Germany in 2018.